SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending as its CEO made a significant insider stock purchase, signaling strong confidence, while rumors of a potential partnership with OpenAI to sell ads are igniting community speculation about a major growth catalyst for the recently oversold ad-tech stock.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is experiencing extreme volatility and massive trading volume as escalating Middle East tensions and concerns over oil supply routes drive crude prices higher. The community is actively debating the stock's short squeeze potential, with bullish traders eyeing significant upside while others caution about profit-taking and its recent offering price.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Escalating US-Iran tensions and concerns over the critical Strait of Hormuz are driving USO, with community debate sharply divided between expectations of prolonged supply disruptions and significant oil price increases versus anticipation of a rapid de-escalation and market interventions.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending following a strong earnings report that exceeded expectations and significantly raised future guidance, fueled by robust demand for its AI chips and a new partnership with OpenAI. The company's optimistic forecast for AI revenue is sparking intense discussion, with many anticipating continued growth, while some express caution about valuation and broader market conditions affecting the post-earnings momentum.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI Corp. is trending following its strong Q4 earnings report, reaffirming impressive future revenue growth guidance, and securing significant new defense contracts including missile propulsion systems and multi-domain swarming autonomy projects. The community is actively discussing the company's potential as a transformative player in defense AI and drone technology, with many likening it to early-stage industry leaders, further amplified by high short interest and expectations for a major upside move.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following its Q4 results and reaffirmed conservative 2026 guidance, which has ignited widespread community frustration over perceived management missteps and undervaluation. Despite the board authorizing a share buyback aimed at boosting value and potentially combating persistent short interest, investors are keenly awaiting upcoming Rezzayo data and new customer partnerships as crucial catalysts.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending following a significant stock drop after releasing Phase 2 data for its HLP004 GAD treatment, sparking community debate over the trial's mixed efficacy signals and whether the market is overreacting to what the company frames as clinically meaningful results.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is trending following its Q4 earnings, which initially saw confusion over EPS figures before being clarified as an inline beat with robust revenue growth and record customer assets. The community is sharply divided, debating whether ongoing dilution concerns and historical stock performance outweigh these strong operational metrics, with many perceiving the stock as deeply undervalued in the fintech brokerage space.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd ($INDO) is trending amidst sharply rising crude oil prices and escalating geopolitical tensions threatening global oil supply, leading the community to anticipate a significant short squeeze. Many investors are drawing parallels to its explosive 2022 run, eagerly awaiting drilling updates as they navigate concerns about market manipulation and potential dilution.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is trending due to its robust community and innovative "AirLock" mechanism, which has over 40% of its supply locked, driving strong bullish sentiment and outperformance within the Solana memecoin ecosystem amidst market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CorMedix (NASDAQ:CRMD) Issues Earnings Results, Misses Estimates By $0.70 EPS

CorMedix (NASDAQ:CRMD - Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.70...

<ul class="summary-bullets"><li>CorMedix’s Q4 revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio.</li><li>Total operating expenses for Q4 rose to $48.2 million, up 181% year-on-year.</li><li>CorMedix ended 2025 with $148.5 million in cash, cash equivalents, and short-term investments.</li></ul>CorMedix Inc. (CRMD) stock gained attention on Thursday, after the company announced its fourth-quarter (Q4) and full-year financial results for 2025, reporting a 312% year-on-year (YoY) jump in revenue.&nbsp;The company reported Q4 revenue of $128.6 million and an earnings per share (EPS) of $0.16. Though CorMedix’s revenue surpassed analysts’ consensus estimate of $127 million, EPS came in way below the estimated $0.82, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2><a href="https://stocktwits.com/symbol/CRMD">CorMedix stock</a> traded over 11% lower on Thursday morning. However, on Stocktwits, retail sentiment around the stock flipped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘high’ from ‘low’ in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_05_092009_png_aaa43e3104.webp" alt="CRMD’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Mar. 5, 2026 | Source: Stocktwits" width="930" height="102"><figcaption>CRMD’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Mar. 5, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they are going long on the stock and hope to keep it until it climbs back to double digits.<stembedurl>https://stocktwits.com/JamesTiberius/message/646666139</stembedurl><h2 class="st-heading-2">Revenue Growth Driven by DefenCath and Melinta Acquisition</h2>CorMedix’s Q4 revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio. The Melinta revenue reflects the company’s first full quarter of contribution since its August 2025 acquisition.&nbsp;Total operating expenses for Q4 rose to $48.2 million, up 181% YoY. The expense increase primarily stems from the Melinta acquisition and includes $4.1 million in one-time costs, such as severance and integration expenses.&nbsp;<blockquote>“I am proud of the company’s progress over the past year as we have accelerated the expansion of patient access for DefenCath, completed our acquisition and integration of Melinta, and saw progress in our two ongoing Phase 3 clinical programs for Rezzayo prophylaxis and DefenCath in TPN.”-Joe Todisco, Chairman and CEO, CorMedix&nbsp;</blockquote>CorMedix ended 2025 with $148.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash.CRMD stock has declined by over 37% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/help-stock-tanks-despite-strong-phase-2-results-for-anxiety-treatment-retail-buys-the-dip-ignoring-market-s-pessimism/cZdQHEpRI3O">HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Tumble Over 11% Today?

The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16. 

Equity

CorMedix (CRMD) Lags Q4 Earnings Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of -29.07% and +1.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Cormedix Earnings Review: Q4 Summary

Royce & Associates LP Buys New Stake in CorMedix Inc $CRMD

Royce & Associates LP purchased a new stake in CorMedix Inc (NASDAQ:CRMD - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission...

CorMedix (CRMD) Projected to Post Quarterly Earnings on Thursday

CorMedix (NASDAQ:CRMD) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 5. (View Earnings Report at...

ANI Pharmaceuticals (ANIP) Surpasses Q4 Earnings and Revenue Estimates

ANI (ANIP) delivered earnings and revenue surprises of +17.32% and +6.04%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates

Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -166.67% and +0.23%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?

CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.

Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?

CorMedix heads into Q4 earnings with DefenCath sales, Melinta product contributions, and its muted 2026 guidance firmly in focus.

$CRMD Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.18 down -18.18% YoY
• Reported revenue of $128.62M up 312.10% YoY
• CorMedix reiterates its 2026 guidance, projecting net revenue between $300M and $320M and adjusted EBITDA between $100M and $125M, reflecting its strategic outlook.

Stocktwits

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of $0.18 down -18.18% YoY
• Reported revenue of $128.62M up 312.10% YoY
• CorMedix reiterates its 2026 guidance, projecting net revenue between $300M and $320M and adjusted EBITDA between $100M and $125M, reflecting its strategic outlook.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $COST earnings Thursday?

Costco Wholesale Corp

Stocktwits Polls

Significant shareholder frustration and criticism target the CEO's communication and management, blaming him for the stock's recent underperformance and perceived disregard for investors.

Uncertainty surrounds the impact of post-TDAPA reimbursement cuts on DefenCath pricing and future profitability, despite strong recent financial reporting.

Hopes are high for substantial share buybacks from the authorized $75 million program to support the stock price, but specific actions remain unclear to investors.

Despite significant revenue growth and favorable financial metrics like low P/E ratios, many users debate why the stock trades at distressed biotech multiples.

CRMD
CorMedix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Earnings Recap

Latest CRMD News

CRMDCorMedix Inc